UY36748A - Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen - Google Patents
Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienenInfo
- Publication number
- UY36748A UY36748A UY0001036748A UY36748A UY36748A UY 36748 A UY36748 A UY 36748A UY 0001036748 A UY0001036748 A UY 0001036748A UY 36748 A UY36748 A UY 36748A UY 36748 A UY36748 A UY 36748A
- Authority
- UY
- Uruguay
- Prior art keywords
- pharmaceutical compositions
- modulators
- aminopiridine
- heteroarilo
- irak
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 101710199010 Interleukin-1 receptor-associated kinase 4 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1877DE2015 | 2015-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY36748A true UY36748A (es) | 2016-12-30 |
Family
ID=56322320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001036748A UY36748A (es) | 2015-06-24 | 2016-06-23 | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10294229B2 (enExample) |
| EP (1) | EP3313840B1 (enExample) |
| JP (1) | JP6843775B2 (enExample) |
| CN (1) | CN107849039B (enExample) |
| AR (1) | AR105113A1 (enExample) |
| ES (1) | ES2745525T3 (enExample) |
| TW (1) | TW201718571A (enExample) |
| UY (1) | UY36748A (enExample) |
| WO (1) | WO2016210034A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR105114A1 (es) * | 2015-06-24 | 2017-09-06 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituida con heteroarilo |
| WO2018071794A1 (en) * | 2016-10-14 | 2018-04-19 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| SMT202100568T1 (it) | 2017-05-11 | 2021-11-12 | Bristol Myers Squibb Co | Tienopiridine e benzotiofeni utili come inibitori di irak4 |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| AU2018338314B2 (en) | 2017-09-22 | 2024-12-12 | Kymera Therapeutics, Inc | Protein degraders and uses thereof |
| TWI876442B (zh) * | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| EP3817748A4 (en) | 2018-07-06 | 2022-08-24 | Kymera Therapeutics, Inc. | TRICYCLIC CRBN LIGANDS AND USES THEREOF |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| WO2020036979A1 (en) | 2018-08-13 | 2020-02-20 | Gilead Sciences, Inc. | Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors |
| WO2020036830A1 (en) | 2018-08-13 | 2020-02-20 | Gilead Sciences, Inc. | Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors |
| TWI727392B (zh) | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | 噻二唑irak4抑制劑 |
| SG11202105424PA (en) | 2018-11-30 | 2021-06-29 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CN109836376B (zh) * | 2019-04-10 | 2022-03-22 | 江苏汉阔生物有限公司 | 一种以2，3-吡啶二羧酸为原料制备2-氯代烟酸的方法 |
| CN114127075B (zh) | 2019-07-18 | 2024-05-14 | 百时美施贵宝公司 | 可用作IRAK4抑制剂的吡唑并[3,4-d]吡咯并[1,2-b]哒嗪基化合物 |
| JP7570399B2 (ja) | 2019-07-18 | 2024-10-21 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用な三環式ヘテロアリール化合物 |
| CN114174304B (zh) * | 2019-07-23 | 2024-05-17 | 百时美施贵宝公司 | 可用作irak4抑制剂的噻吩并吡啶基化合物和噻唑并吡啶基化合物 |
| JP7682154B2 (ja) | 2019-08-06 | 2025-05-23 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用な二環ヘテロ環式化合物 |
| WO2021067967A1 (en) * | 2019-10-04 | 2021-04-08 | University Of Kentucky Research Foundation | Preparation of pyrazolo[3,4-b]pyridines as antimalarials |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| JP2023509366A (ja) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| WO2021127188A1 (en) | 2019-12-18 | 2021-06-24 | Elanco Tiergesundheit Ag | Isoxazoline derivatives as pesticides |
| WO2021158495A1 (en) | 2020-02-03 | 2021-08-12 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors |
| CN115335381A (zh) * | 2020-02-19 | 2022-11-11 | 新锐思生物制药股份有限公司 | 白细胞介素-1受体相关激酶的双功能降解剂及其治疗用途 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| MX2023007852A (es) | 2020-12-30 | 2023-07-07 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| CN117813307A (zh) | 2021-08-18 | 2024-04-02 | 新锐思生物制药股份有限公司 | 白介素-1受体相关激酶的双官能降解物及其治疗用途 |
| WO2023076556A1 (en) | 2021-10-29 | 2023-05-04 | Kymera Therapeutics, Inc. | Irak4 degraders and synthesis thereof |
| IL314437A (en) | 2022-01-31 | 2024-09-01 | Kymera Therapeutics Inc | IRAK joints and their uses |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002102800A1 (en) | 2001-06-15 | 2002-12-27 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
| JP4529685B2 (ja) | 2002-06-28 | 2010-08-25 | アステラス製薬株式会社 | ジアミノピリミジンカルボキサミド誘導体 |
| MXPA05007503A (es) | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
| CN1820001A (zh) | 2003-07-10 | 2006-08-16 | 神经能质公司 | 经取代的杂环二芳基胺类似物 |
| GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| US8273759B2 (en) | 2007-06-08 | 2012-09-25 | Bayer Cropscience Ag | Fungicide heterocyclyl-pyrimidinyl-amino derivatives |
| WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| WO2010058846A1 (ja) | 2008-11-21 | 2010-05-27 | アステラス製薬株式会社 | ４，６-ジアミノニコチンアミド化合物 |
| CA2745004C (en) | 2008-11-28 | 2014-07-15 | Kowa Company, Ltd. | Pyridine-3-carboxyamide derivative |
| JP2012529535A (ja) | 2009-06-12 | 2012-11-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼモジュレーターとして有用なニコチンアミド化合物 |
| EP2493863B1 (en) | 2009-10-30 | 2015-02-25 | Janssen Pharmaceutica NV | Phenoxy-substituted pyrimidines as opioid receptor modulators |
| WO2011093501A1 (ja) | 2010-02-01 | 2011-08-04 | 日本ケミファ株式会社 | Ｇｐｒ１１９作動薬 |
| KR20140026532A (ko) | 2011-04-29 | 2014-03-05 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 키나제 억제제 |
| ES2575604T3 (es) | 2012-01-13 | 2016-06-29 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa |
| US8987311B2 (en) * | 2012-01-13 | 2015-03-24 | Bristol-Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| ES2686500T3 (es) | 2012-01-13 | 2018-10-18 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con heterocíclicos, útiles como inhibidores de cinasas |
| WO2014058685A1 (en) * | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| MX2015005562A (es) | 2012-11-08 | 2015-07-23 | Squibb Bristol Myers Co | Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa. |
| WO2014074657A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
| WO2014074660A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES |
| TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| UY35935A (es) | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 |
| AR105114A1 (es) * | 2015-06-24 | 2017-09-06 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituida con heteroarilo |
-
2016
- 2016-06-23 AR ARP160101892A patent/AR105113A1/es unknown
- 2016-06-23 UY UY0001036748A patent/UY36748A/es not_active Application Discontinuation
- 2016-06-23 CN CN201680040987.7A patent/CN107849039B/zh active Active
- 2016-06-23 TW TW105119777A patent/TW201718571A/zh unknown
- 2016-06-23 JP JP2017566643A patent/JP6843775B2/ja active Active
- 2016-06-23 US US15/738,362 patent/US10294229B2/en active Active
- 2016-06-23 EP EP16734538.8A patent/EP3313840B1/en active Active
- 2016-06-23 WO PCT/US2016/038858 patent/WO2016210034A1/en not_active Ceased
- 2016-06-23 ES ES16734538T patent/ES2745525T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201718571A (zh) | 2017-06-01 |
| US20180186799A1 (en) | 2018-07-05 |
| EP3313840A1 (en) | 2018-05-02 |
| EP3313840B1 (en) | 2019-07-24 |
| ES2745525T3 (es) | 2020-03-02 |
| JP2018522859A (ja) | 2018-08-16 |
| JP6843775B2 (ja) | 2021-03-17 |
| AR105113A1 (es) | 2017-09-06 |
| US10294229B2 (en) | 2019-05-21 |
| CN107849039B (zh) | 2020-07-03 |
| WO2016210034A1 (en) | 2016-12-29 |
| CN107849039A (zh) | 2018-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY36748A (es) | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen | |
| UY36747A (es) | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen | |
| UY36749A (es) | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CO2019007839A2 (es) | Composiciones y métodos para inhibir la acción de la arginasa | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| CL2017002483A1 (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
| MX2017000450A (es) | Compuestos terapeuticos inhibidores. | |
| CL2018000687A1 (es) | Nuevos compuestos bicíclicos como inhibidores de atx. | |
| SV2017005561A (es) | Metodos para tratar infecciones por el virus filoviridae | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| MX2016014253A (es) | Inhibidores de desmetilasa-1 especifica de lisina. | |
| CU20160162A7 (es) | Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen | |
| SV2016005257A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| MX2016011035A (es) | Compuestos arilo, heteroarilo y heterociclicos para el tratamiento de trastornos mediados por complemento. | |
| ECSP19083923A (es) | Inhibidores pirazólicos de magl | |
| CU24419B1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas | |
| MX2018001054A (es) | Compuestos heterociclicos utiles como moduladores de factor de necrosis tumoral (tnf) alfa. | |
| CO2019005059A2 (es) | Inhibidores de magl | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| SV2017005405A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| CO2019005038A2 (es) | Inhibidores de magl | |
| MX2019001011A (es) | Compuestos farmaceuticos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20201204 |